CG MedTech Co Ltd

CG MedTech operates with a fully diluted share count of 103,259,036 shares, matching its basic share count, indicating no dilution from stock options or convertible securities. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability is not yet quantified in the valuation snapshot, but its EBIT estimate of 9.1 billion KRW suggests a potential for strong operating performance. Analysts expect a significant revenue increase, with a mean revenue estimate of 69.45 billion KRW compared to the last actual revenue of 47.23 billion KRW. CG MedTech's business is divided into two segments: the Medical Device Business and the Electric Energy Business. The Medical Device Business is the primary revenue driver, focusing on orthopedic medical devices, while the Electric Energy Business deals with electricity meters and calorimeters. The company's geographic exposure is primarily concentrated in South Korea, with no disclosed international revenue segments. Looking ahead, the company is expected to see a substantial revenue increase, with a mean revenue estimate of 69.45 billion KRW for the current fiscal year. This represents a significant growth trajectory, although the exact drivers of this growth are not yet detailed in the available data. The company's risk assessment indicates a low dilution risk, with no immediate pressure from share issuance or convertible instruments. However, the absence of liquidity data and the lack of balance-sheet inputs present a challenge in fully assessing the company's financial health. Recent events and filings have not been disclosed in the available data, so no specific recent developments can be cited at this time.